Shots:

• The first patient has been dosed in a P-I CIBI323A101 study evaluating IBI323 (anti-LAG-3/PD-L1 bispecific Ab) in patients with advanced solid tumors. The trial is being conducted in China
• The purpose of the P-I dose-escalation and expansion study is to evaluate the safety- tolerability- optimal dosage- and preliminary efficacy of IBI323 in patients with advanced malignant tumors whose cancer progressed on SoC treatment
• The preclinical studies showed that IBI323 effectively blocks both the PD-1/PD-L1 and LAG-3 pathways and enhance the T lymphocyte activation compared with the combination of anti-PD-L1 and anti-LAG mAb

  Ref: PR Newswire | Image: Innovent